These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25134047)

  • 61. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
    Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.
    Fishman M; Wenzel K; Vo H; Wildberger J; Burgower R
    Addiction; 2021 Mar; 116(3):548-557. PubMed ID: 32621368
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Behavioral naltrexone therapy: an integrated treatment for opiate dependence.
    Rothenberg JL; Sullivan MA; Church SH; Seracini A; Collins E; Kleber HD; Nunes EV
    J Subst Abuse Treat; 2002 Dec; 23(4):351-60. PubMed ID: 12495797
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adherence to extended release naltrexone: Patient and treatment characteristics.
    Chang G; Crawford M; Pitts M; Schein AZ; Goodwin K; Enggasser JL
    Am J Addict; 2018 Sep; 27(6):524-530. PubMed ID: 30106489
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen Ø; Waal H
    Br J Psychiatry; 2009 Jun; 194(6):541-6. PubMed ID: 19478295
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
    Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients.
    Kidorf M; Neufeld K; Brooner RK
    Subst Use Misuse; 2004; 39(13-14):2215-38. PubMed ID: 15603002
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Naltrexone pharmacotherapy for opioid dependent federal probationers.
    Cornish JW; Metzger D; Woody GE; Wilson D; McLellan AT; Vandergrift B; O'Brien CP
    J Subst Abuse Treat; 1997; 14(6):529-34. PubMed ID: 9437624
    [TBL] [Abstract][Full Text] [Related]  

  • 70. DSM IV axis II traits can influence compliance to treatment with oral naltrexone: a preliminary study on 30 opiate dependent patients.
    Streel E; Chenut C; Papageorgiou C; Verbanck P
    Addict Behav; 2014 Jan; 39(1):321-4. PubMed ID: 24090623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Naltrexone: a short-term treatment for opiate dependence.
    Greenstein RA; O'Brien CP; McLellan AT; Woody GE; Grabowski J; Long M; Coyle-Perkins G; Vittor A
    Am J Drug Alcohol Abuse; 1981; 8(3):291-300. PubMed ID: 7340503
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Behavior analysts in the war on poverty: Developing an operant antipoverty program.
    Silverman K; Holtyn AF; Subramaniam S
    Exp Clin Psychopharmacol; 2018 Dec; 26(6):515-524. PubMed ID: 30265062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders.
    Stoner SA; Arenella PB; Hendershot CS
    PLoS One; 2015; 10(4):e0124613. PubMed ID: 25909320
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antagonist Models for Relapse Prevention and Reducing HIV Risk.
    Woody GE; Krupitsky E; Zvartau E
    J Neuroimmune Pharmacol; 2016 Sep; 11(3):401-7. PubMed ID: 26922659
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Utility of Operant Conditioning to Address Poverty and Drug Addiction.
    Silverman K; Holtyn AF; Toegel F
    Perspect Behav Sci; 2019 Sep; 42(3):525-546. PubMed ID: 31976448
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Employment outcomes of substance use disorder patients enrolled in a therapeutic workplace intervention for drug abstinence and employment.
    Holtyn AF; Toegel F; Arellano M; Subramaniam S; Silverman K
    J Subst Abuse Treat; 2021 Jan; 120():108160. PubMed ID: 33298300
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Behavioral factors predicting response to employment-based reinforcement of cocaine abstinence in methadone patients.
    Holtyn AF; Washington WD; Knealing TW; Wong CJ; Kolodner K; Silverman K
    Transl Issues Psychol Sci; 2016 Jun; 2(2):192-202. PubMed ID: 27777965
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reduction of classroom noise levels using group contingencies.
    Ring BM; Sigurdsson SO; Eubanks SL; Silverman K
    J Appl Behav Anal; 2014; 47(4):840-4. PubMed ID: 25175843
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discounting of employment opportunities with urine drug testing requirements in opioid users enrolled in the Therapeutic Workplace.
    Traxler HK; Silverman K; Koffarnus M
    J Vocat Rehabil; 2023; 59(2):183-190. PubMed ID: 37810907
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.
    Perez-Macia V; Martinez-Cortes M; Mesones J; Segura-Trepichio M; Garcia-Fernandez L
    Patient Prefer Adherence; 2021; 15():999-1015. PubMed ID: 34040354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.